Expression and Clinical Significance of Co-inhibitory Molecules TIGIT/CD155 and PD-1 in Chronic Lymphocytic Leukemia.
10.19746/j.cnki.issn.1009-2137.2025.01.008
- Author:
Rui ZHANG
1
;
Shuang CHEN
1
;
Ting-Ting LUO
1
;
Jian-Hua QU
1
Author Information
1. Laboratory of Hematology Center, The First Affiliated Hospital of Xinjiang Medical Universiry, Hematology Institute of Xinjiang Uygur Autonomous Region, Urumqi 830054, Xinjiang Uygur Autonomous Region, China.
- Publication Type:Journal Article
- Keywords:
chronic lymphocytic leukemia;
inhibitory molecule;
PD-1;
TIGIT
- MeSH:
Humans;
Leukemia, Lymphocytic, Chronic, B-Cell/immunology*;
Receptors, Immunologic/metabolism*;
Programmed Cell Death 1 Receptor/metabolism*;
T-Lymphocytes, Regulatory/metabolism*;
Receptors, Virus/metabolism*;
CD4-Positive T-Lymphocytes/metabolism*;
Male;
Female;
Middle Aged;
Flow Cytometry;
Clinical Relevance
- From:
Journal of Experimental Hematology
2025;33(1):54-61
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression of co-inhibitory molecules TIGIT/CD155 and PD-1 on CD4+T cells and Treg cells in peripheral blood of patients with chronic lymphocytic leukemia (CLL) and analyze their clinical significance.
METHODS:The expression of PD-1 and TIGIT on CD4+T cells and Treg cells was detected by flow cytometry in 40 CLL patients and 20 healthy controls. Additionally, the expression of CD155 on peripheral blood B cells and DC cells of the enrolled subjects was detected.
RESULTS:The proportions of PD-1+TIGIT+CD4+T cells, PD-1+TIGIT+Treg cells and CD155+DC cells in peripheral blood of CLL patients were significantly higher than those of healthy controls ( P < 0.05). The proportions of PD-1+TIGIT+CD4+T cells and PD-1+TIGIT+Treg cells in CLL patients were significantly higher than those of PD-1+TIGIT-CD4+T cells and PD-1+TIGIT-Treg cells, respectively ( P < 0.05). Both PD-1+TIGIT+CD4+T cells and PD-1+TIGIT+Treg cells were positively correlated with the level of CD155+DC cells (r =0.742, r =0.766). With the progression of Binet stage, the proportions of PD-1+TIGIT+CD4+T cells, PD-1+TIGIT+Treg cells, and CD155+DC cells gradually increased ( P < 0.05), and the aforementioned three types cells were all increased in patients with CD38≥30%, IGVH unmutated, or poor prognosis due to chromosomal abnormalities ( P < 0.05).
CONCLUSION:Co-inhibitory molecules PD-1 and TIGIT may be involved in immunodepletion in patients with advanced CLL, which has clinical prognostic value. Dual inhibitor molecular targeted therapy provides a new direction for the individualized treatment of CLL.
